When.com Web Search

  1. Ads

    related to: tricor medication

Search results

  1. Results From The WOW.Com Content Network
  2. Fenofibrate - Wikipedia

    en.wikipedia.org/wiki/Fenofibrate

    Fenofibrate (sold under the brand name Tricor among others), is an oral medication of the fibrate class used to treat abnormal blood lipid levels. [3] It is less commonly used compared to statins because it treats a different type of cholesterol abnormality to statins.

  3. Researchers Say AbbVie's Tricor Reduced Severity Of ... - AOL

    www.aol.com/news/researchers-abbvies-tricor...

    AbbVie Inc (NYSE: ABBV) shares popped Tuesday after researchers found that the large-cap pharma's cholesterol-lowering drug Tricor could work against SARS-CoV2, the virus that causes COVID-19.What ...

  4. Abbott's deal with Teva keeps generic TriCor off the ... - AOL

    www.aol.com/news/2009-12-01-abbotts-deal-with...

    Now, Abbott has managed to seal a deal with generic-drug maker Teva Pharmaceuticals Industries that would stave off generic competition for TriCor -- yet again -- until March 2011 at least.

  5. PPAR agonist - Wikipedia

    en.wikipedia.org/wiki/PPAR_agonist

    PPARα (alpha) is the main target of fibrate drugs, a class of amphipathic carboxylic acids (clofibrate, gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate). They were originally indicated for dyslipidemia of cholesterol and more recently for disorders characterized by high triglycerides.

  6. Fibrate - Wikipedia

    en.wikipedia.org/wiki/Fibrate

    In combination with statin drugs, fibrates cause an increased risk of rhabdomyolysis, idiosyncratic destruction of muscle tissue, leading to kidney failure. The less lipophilic statins are less prone to cause this reaction, and are probably safer to be combined with fibrates than the more lipophilic statins are. Drug toxicity includes acute ...

  7. AbbVie - Wikipedia

    en.wikipedia.org/wiki/AbbVie

    [52] [53] Forest Laboratories, a subsidiary of AbbVie, has been accused of using unlawful deals to prevent generic versions of its Alzheimer's disease drug, Namenda, from entering the market. [54] [55] In 2018, AbbVie agreed to pay $25 million to resolve allegations that it made use of kickback schemes to promote its cholesterol drug Tricor. [56]